Healthcare
InMode Ltd.(INMD)
Live Price
Offline$13.45
-0.30% today
1Y Change
-7.04%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $920.00M
- Revenue Growth
- -6.2%
- EPS Growth
- -36.7%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
InMode Ltd. (INMD) is a Healthcare stock with a market cap of $920.00M and listed on NASDAQ. The stock last traded around $13.45 and down 7.0% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of -6.2%, EPS growth of -36.7%, a dividend yield of 0.0%. What stands out right now is revenue -6.2%, EPS -36.7%, free cash flow -36.1% with operating margin 23.0% and ROIC 10.4%. Valuation is more restrained than many high-expectation growth names at P/E 9.8 and price/sales 2.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines INMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-6.2% vs +7.6% peer median
Operating Margin
Above sector median
+23.0% vs +19.4% peer median
P/E
Below sector median
9.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 28, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -6.2% and EPS is at -36.7%, with operating margin around 23.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 28, 2026 | โ | -1.8% | +1.3% | -2.8% |
2026 Feb 10, 2026 | +10.5% | -2.6% | -1.1% | -10.1% |
2025 Nov 5, 2025 | +8.3% | -0.6% | +0.6% | -1.3% |
Benchmark Edge
INMD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INMD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INMD Max Drawdown
-23.23%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INMD and SPY.
Company Overview
InMode Ltd.
NASDAQ Global Select
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
- Leadership
- Moshe Mizrahy
- IPO Date
- Aug 8, 2019
- Employees
- 599
- Street Address
- Tavor Building
- Mailing
- Yokne'am, 2069206
- Region
- Yokne'am, IL
- Reporting Currency
- USD
- Investor Line
- 972 4 909 6313
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 9.8
- EV/EBITDA
- 6.0
- Price/Sales
- 2.5
- Price/Book
- 1.3
Growth
- Revenue
- -6.2%
- EPS
- -36.7%
- Free Cash Flow
- -36.1%
Profitability
- Gross Margin
- 78.5%
- Operating Margin
- 23.0%
- Net Margin
- 25.3%
- ROE
- 14.5%
- ROIC
- 10.4%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 9.88
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.